SPE/MPD MiniTec conference at MD&M West features medical polymer innovations, sustainability keynote, and device design ...
Wright Corporation (NYSE: CW) expects to release its fourth quarter and full-year 2025 financial results after the close of trading on Wednesday, February 11, 2026. A webcast conference call will be ...
Q2 2026 Earnings Call Transcript January 7, 2026 Operator: Good afternoon, and welcome to Applied Digital’s Fiscal Second ...
Q1 2026 Earnings Call Transcript January 7, 2026 MSC Industrial Direct Co., Inc. beats earnings expectations. Reported EPS is ...
Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases, today ...
Motorola has finally entered the book-style foldable phone market with the introduction of the Razr Fold. It’ll go up against ...
Marking a significant step in advancing the professionalization of career guidance and career development services in Qatar, the diploma was developed by QCDC in collaboration with EduCluster Finland, ...
Learn all about the best NFL betting sites as our expert ranks and reviews the best bookmakers for NFL betting the UK has to ...
Opinion
9hOpinion
Shrubs, shamans and love stones: why the WHO has gone Goopy for traditional medicine
Mongolian shamans beat wicker drums to summon ancestral spirits. A Peruvian man in a headdress unleashes a piercing ululation. And a man from Kentucky tells me the body can rid itself of cancer if you ...
Software Experts has announced its recognition of Webroot as a trusted identity protection solution for 2026, highlighting the company's integrated approach to protecting personal data across devices, ...
"In the first quarter, we generated over €275 million in revenue, representing organic growth of 6.0%. Thanks to this growth trajectory and our financial discipline, we can confirm all of our FY2026 ...
Continuing Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA) Following Positive Phase 2b RSVHR Results for Zelicapavir, an N-Protein Inhibitor in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback